Guidance for Vanda Pharma (VNDA)
Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
---|---|---|---|---|---|---|
2022 | N/A | N/A | $240.00M – 280.00M | $313.62M | Lowered | Details |
2022 | $240.00 – $280.00 | N/A | N/A | N/A | = Maintained | Details |
Q3 2022 | N/A | N/A | $240.00M – 280.00M | $265.10M | = Maintained | Details |
2020 | N/A | N/A | $240.00M – 260.00M | $274.60M | = Maintained | Details |
2020 | N/A | N/A | $240.00M – 260.00M | $251.05M | = Maintained | Details |
2020 | N/A | N/A | $240.00M – 260.00M | $247.77M | = Maintained | Details |
2019 | N/A | N/A | $215.00M – 225.00M | $221.36M | = Maintained | Details |
2019 | N/A | N/A | $215.00M – 225.00M | $219.56M | = Maintained | Details |
2019 | N/A | N/A | $215.00M – 225.00M | $224.80M | = Maintained | Details |
Q3 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |